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servation, and 0.005 events per application year in the other 
group.  Conclusions: Because of their feasibility and safety 
over years, DAM tablets may be a valuable long-term thera-
peutic alternative.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Maintenance treatment, especially with methadone, 
has become the standard treatment for opioid depen-
dence in numerous countries and has been recommend-
ed by international organizations  [1–4] . Not all opioid-
dependent patients, however, fully respond to methadone 
maintenance treatment  [5] . The medical prescription of 
intravenous diacetylmorphine (DAM) to chronic treat-
ment refractory heroin-dependent patients has been con-
sidered as a second-line therapy in several countries and 
its feasibility and effectiveness has been confirmed in co-
hort studies  [6, 7] and controlled trials  [8–10] . Patients 
who had never or not regularly injected had to be exclud-
ed from intravenous heroin substitution for ethical con-
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 Abstract 
 Background: To assess the long-term course of the feasibil-
ity and safety of orally administered heroin [diacetylmor-
phine (DAM)] tablets in substitution treatment of severely 
addicted opioid users.  Design: Open-label, prospective co-
hort study with 2 non-randomly assigned treatment arms: 
DAM tablets only (n = 128) or DAM tablets combined with 
injected DAM and/or other opioids (n = 237). The average 
duration of the observation period was 62 months. Study 
endpoints were the time to discharge from treatment and 
the number of serious adverse events.  Results: Both patient 
groups had a higher than 70% retention rate after the first 48 
months of treatment, with similar long-term retention rates 
(after 8 years both groups had retention over 50%). The phy-
sician-verified rate of serious adverse events was 0.01 events 
per application year among the exclusively oral substitution 
group (intention-to-treat analysis) during the last year of ob-
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siderations as they cannot be introduced to an application 
form which bears more health risks. The reasons for the 
oral use of illegal opioids vary and include cultural influ-
ences, fear of risks of infection and the inability to find 
veins for injection. Consequently, alternatives in HAMT 
were explored by studying inhalable heroin in the Neth-
erlands  [11] , morphine tablets  [12] , and intramuscular 
(i.m.) and oral application (p.o.) modes in Switzerland 
 [13, 14] . The latter options were explored because inhal-
able heroin was not possible in Switzerland or many oth-
er countries for legal reasons. Among other alternatives, 
the combination of immediate-release and slow-release 
tablets of DAM  [15] , as introduced within the Swiss 
HAMT, provided the most promising results with respect 
to retention rates and serious adverse events  [16] . Both 
galenic forms were developed by the Swiss Federal Office 
of Public Health in 1998 for use in heroin-assisted thera-
py and each contains 200 mg of diamorphine hydrochlo-
ride.
 Gyr et al.  [17] compared high-dose intravenous (200–
690 mg) and oral (capsules, controlled-release tablets) 
DAM preparations, and found DAM to be detectable in 
plasma only after intravenous administration. Oral doses 
and dosage intervals were described to be sufficient to 
produce flash and high effects among participants. In a 
further study, oral DAM ( ! 600 mg) was well absorbed in 
the intestine, but underwent excessive first-pass deacety-
lation to morphine with a rather high mean morphine 
bioavailability of 64–72%, but resulted in negligible sys-
temic DAM and monoacetylmorphine exposures  [14] . 
Oral DAM was absorbed more rapidly and to a greater 
extent than a concomitant test dose of morphine-d3  [14] . 
Confirming the preliminary results on DAM, Halbsguth 
et al.  [18] demonstrated that morphine bioavailability de-
pends on:
 (1) The particular drug administered (morphine ab-
sorption from oral DAM was found to be faster than from 
oral morphine, leading to higher C max and shorter t max 
values observed in both the investigated group of opioid-
dependent and opioid-naïve subjects, n = 8 per group). 
 (2) Prior opioid exposure (for the systemic morphine 
exposure achieved from oral DAM a doubling of the 
maximum morphine concentration at about half the 
maximum time were observed in opioid-dependent com-
pared with opioid-naïve subjects). 
 (3) Dose (a dose effect was observed for oral DAM, in-
creasing morphine bioavailability up to 64% at the high-
est dose of 598 mg; moreover, morphine bioavailability 
increased with co-administration of DAM). 
 The study  [18] presents pharmacokinetic advantages 
of oral DAM over oral morphine, resulting in a compli-
ance-relevant faster onset of drug and more efficient bio-
availability for substitution treatment. Thus, morphine 
from oral DAM was more rapidly and more completely 
absorbed than from oral morphine. Therefore, oral DAM 
could be seen as an active pro-drug of morphine reaching 
a higher level of systemic morphine faster than from mor-
phine itself  [14] .
 As previously mentioned  [16] , the results of an inten-
tion-to-treat analysis of the current open-label prospec-
tive cohort study for DAM tablets within the Swiss 
HAMT after an observation period of 1 year have been 
reported. DAM p.o. treatment was part of the overall 
Swiss HAMT that addressed the treatment needs of pa-
tients ineligible for DAM i.v. or who had or wanted to 
switch to DAM p.o. (see below for details). In the Frick et 
al. study  [16] , the retention rates after 1 year in DAM tab-
lets-only group (0.804, 95% CI: 0.735–0.873) and in the 
subgroup combining oral application of DAM with intra-
venous application or other opioids (0.843, 95% CI: 0.797–
0.889) were higher than in the historical controls, i.e. the 
Swiss cohort of patients that had been intravenously sub-
stituted with DAM (1-year retention rate = 0.70). In addi-
tion, rates of serious adverse events under study medica-
tion (tablets only = 0.038 per application year; tablets in 
combination = 0.028 per application year) were compa-
rable to the historical rate of the Swiss heroin-assisted 
treatment (0.043).
 The present analyses report the results for the feasibil-
ity and safety of oral DAM using the same study end-
points with prolonged observation period: for feasibility, 
the period between a patient’s individual start date of oral 
medication and July 2008 was evaluated; for safety, the 
first 2 years after the start of the formal drug approval 
study were used.
 Methods 
 The study design was an open-label prospective cohort study 
with 2 non-randomly allocated treatment arms to be compared. 
Additionally, the pooled cohort of both treatment arms is com-
pared in its long-term outcome (retention from first tablet to July 
28, 2008) to the complete population of injecting DAM users in 
the Swiss HAMT (from individual treatment entry to the same 
time point).
 Eligibility 
Patients who were already admitted to the Swiss heroin-assist-
ed treatment program (for general eligibility criteria for this treat-
ment program for severely addicted opioid users, see  [19] ) were 
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eligible to be enrolled into this study if one or more of the follow-
ing conditions were fulfilled: (1) the status of their veins prohib-
ited further intravenous application of DAM, (2) they had used 
opioids prior to the substitution program exclusively via inhala-
tion or sniffing, and intravenous use, therefore, meant an increase 
in health risk for them, or (3) they wished to reduce their health 
risk gradually or abruptly, but in any case permanently shifting 
from intravenous to the oral application of DAM.
 All 402 patients already receiving DAM tablets in the Swiss 
heroin-assisted treatment, or scheduled to receive such tablets 
from the reference date of each treatment center, were enrolled in 
the study ( fig. 1 ). Twenty-one of the 23 existing Swiss outpatient 
treatment centers recruited patients. For the remaining 2 centers, 
there were no patients fulfilling the inclusion criteria.
 Treatment Allocation and Study Groups 
 All patients were treated according to Swiss heroin-assisted 
treatment protocol, as specified by and under permission of the 
Federal Office of Public Health on a patient-named basis. Treat-
ment included psychosocial services at least once per month, and 
somatic interventions if necessary. Opiate dosage and number of 
administrations were prescribed according to the patient’s needs. 
The treatment centers were open 3 times per day, 7 days per week. 
In groups 1 and 2, no other substitution medication was given (for 
protocol violations, see below). Consumption was monitored by a 
self-reported questionnaire and urinalysis.
 Groups 1 and 2 (Tablets Only). A total of 128 patients received 
a medication regimen providing DAM exclusively in tablet form 
[either immediate-release tablets alone (group 1) or combining 
immediate release and slow-release tablets (group 2)].
 Group 3 (Tablets and Other Opioids). A combination of DAM 
tablets with either injectable DAM or other noninjectable opioids, 
like morphine (as a tablet), was given ( 6 1 dose) to 237 patients 
(group 3). These patients received intravenous applications only 
if there was clear evidence of intravenous use prior to the study. 
With regard to medications other than diamorphine, study group 
3 was designed to be a ‘left over’ category, comprising all combi-
nations of substitution-medication including combinations with 
methadone or morphine tablets. 
 At baseline, 26.5% of all patients in groups 1 and 2, but only 
9.7% of group 3, had never practiced intravenous application of 
heroin or other opioids (  2 test; p  ! 0.001). With respect to vari-
ables predictive for treatment outcome in the cohort entering the 
Swiss HAMT program between January 1, 2001 and February 29, 
2004  [20] , no differences were found between patients receiv -
ing tablets and those receiving only intravenous applications of 
heroin.
 Within the groups described, 25 patients in groups 1 and 2 
(tablets only) and 49 patients in group 3 had not received DAM 
tablets prior to the start of the study. The remaining patients had 
some experience with DAM tablets as part of the Swiss heroin-
assisted treatment. Therefore, this article uses the longest avail-
able observation period per patient for evaluation, and counts the 
duration of oral substitution treatment from the very first day that 
the patient received a DAM tablet.
 Study Period 
 The feasibility of oral DAM medication was evaluated for each 
patient’s longest possible observation period, irrespective of the 
time when he/she was included into the formal drug approval 
study. Thus, the duration of the observation period was counted 
as the days from each patient’s first medication with DAM tablets 
until July 18, 2008 when the database was frozen. On average, pa-
tients in the tablets only groups had an observation period of 
2,253 days (SD 627), while patients in group 3 (tablets and other 
opioids) had 2,237 days (SD 528). Analyses on adverse events were 
Group 1
DAM p.o. IR
40
Group 2
DAM p.o. IR + SR
88
Groups 1 and 2
Intention-to-treat
received ≥1 dose
128
Erroneously enrolled
7
Groups 1 (IR) and 2 (IR + SR)
Substitution exclusively
by tablets
135
Group 3a
DAM p.o. + DAM i.v.
126
Group 3b
DAM p.o. + opioids
111
Group 3
Intention-to-treat
received ≥1 dose
237
Erroneously enrolled
30
Group 3
Tablets in combination
with DAM i.v. or other
267
Enrolled
402
 Fig. 1. Study population. IR = Immediate release; SR = slow release. 
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performed for the second year after the start of the formal drug 
approval study (in most cases: January 2005 to January 2006) in 
order to compare the risk for serious adverse events per applica-
tion year to the risk calculated for the observation period (No-
vember 2003 to December 2004) that was reported by Frick et al. 
 [16] .
 Study Endpoints 
 The main endpoint of the 1-year study by Frick et al.  [16] was 
the retention rate, which was to be compared to the known his-
torical 1-year retention rate of the Swiss heroin substitution pro-
gram, reported to be a proportion of 0.7  [6] . Sample size calcula-
tions were based on this comparison  [16, 21] . Discharge from 
HAMT was defined as either an explicit ending of treatment by a 
respective declaration of the patient, formally excluding the pa-
tient from the treatment for disciplinary reasons according to the 
rules of HAMT  [19] or by a patient-caused interruption of treat-
ment (i.e. not presenting at the treatment center for longer than 6 
weeks without prior information or approval). For this prolonged 
observation period study, the major study endpoint was defined 
as the period between the first day a patient received a DAM tab-
let, and his/her first discharge from HAMT after having received 
oral medication. When comparing patients with any oral applica-
tion (pooled groups 1–3) to those exclusively receiving an intrave-
nous application ( fig. 2 ), latter group’s day of treatment entry was 
counted as the starting point.
 The safety of orally administered DAM was chosen as the sec-
ond major study endpoint and was monitored during the study. 
Data of serious adverse events were collected via the reporting 
system that has been monitoring the safety of heroin prescription 
in the Swiss heroin-assisted treatment since 1994. Physicians’ re-
ports of adverse events were classified according to the Interna-
tional Committee on Harmonization guidelines for clinical trials 
as grade 3 in case of deaths, life-threatening events, hospitaliza-
tions and events causing a permanent noxa or functional disabil-
ity. A critical value of 4.3 serious adverse events per 100 applica-
tion years was chosen as a minimum safety standard from previ-
ous experience with the intravenous application of DAM  [16] .
 Statistical Analysis 
 Time to discharge from HAMT as a major study endpoint dis-
played censored observations at the day, when the database was 
frozen (July 18, 2008). Therefore, survival curves were compared 
by calculating the Kaplan-Meier estimates for the survival func-
tion and a log-rank test. SAS Proc Lifetest was used for calcula-
tions.
 All statistical analyses were performed using intention-to-
treat principles and therefore included patients with protocol vio-
lations (n = 24 in tablets only group) in the originally assigned 
groups. Patient treatment schemes remained unchanged for the 
subsequent years of observation (until July 2008).
 Approval by Research Ethics Board 
 The study protocol, including the extension of the original 
study period, was approved by all 9 cantonal ethics committees 
that were responsible for the participating 21 treatment centers.
 Results 
 Sociodemographic and Other Characteristics at 
Baseline 
 The sociodemographic characteristics have been re-
ported in detail in previous publications  [16, 21] and will 
only be summarized here. The majority of patients were 
men (n = 281; 77.0%), with an average age of 37.1 years (SD 
6.4). Most of the participants were living in rented apart-
ments (n = 266; 72.9%) with 9 people being homeless 
(2.5%). 106 patients had at least part-time employment in 
the unprotected employment market (29.0%).
 Patients had used heroin for longer than a decade be-
fore administration of oral DAM  [16] . They had high so-
matic and mental disease burden, as evidenced by rates 
of 65% for hepatitis C infection, 11% for HIV infection, 
32% for personality disorders, 32% for affective disorders 
and 15% with two and more additional psychiatric diag-
noses in October 2003.
 Major Study Endpoints: Treatment Retention
 The main study endpoint of the prospective cohort 
study was the retention rate.  Figure 3 shows the temporal 
course of this endpoint.
 The retention rate 24 months after the individual start 
date of oral medication for groups 1 and 2 was 80.7% (95% 
CI: 73.6–87.8%), which was somewhat lower than the rate 
of group 3 (87.6%; 95% CI: 83.2–92.0%). For both groups, 
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 Fig. 2. Retention rate in Swiss heroin-assisted treatment by appli-
cation type since start (Kaplan-Meier estimator). 
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however, these retention rates were significantly higher 
after more than 2 years than the 1-year retention rate in 
the historical sample of intravenous heroin-assisted treat-
ment (70%).
 At day 1,349 (3.7 years or 45 months after initial tablets 
medication) survival curves of both conditions intersect-
ed at a retention rate of 72.5% (95% CI for group 3: 67.0–
78.8%). Thereafter, groups 1 and 2 displayed a somewhat 
more favorable retention rate until day 2,472 (after 82 
months or 6.8 years). Then both survival curves inter-
sected a second time at a rate of 56.0% (95% CI for groups 
1 and 2: 44.4–67.7%). Groups 1 and 2 displayed a very 
stable treatment retention rate after this period lasting at 
56.0% for more than 12 years (or 150 months) for the lon-
gest observed patients. Group 3 displayed a retention rate 
of 50.3% (95% CI: 39.0–61.4%) after 8.8 years (or 106 
months), which remained stable to the last observation 
after 11.4 years (or 139 months). Both retention rates can 
be seen as remarkably high given the length of the treat-
ment period. A formal log-rank test to compare the 
groups was not possible because of the nonproportional 
hazard rates. The Kolmogorov-Smirnov test for differ-
ences between the shapes of both survival curves yielded 
a value of p  ! 0.001. This indicates potential disadvan-
tages for the tablets only medication regimen during the 
first 3 years which were outweighed by the advantages 
during the years 4–6; there were no meaningful differ-
ences in the long run after 6 years.
 Figure 2 shows treatment retention for all DAM p.o. 
groups combined in comparison to DAM i.v. DAM p.o. 
was associated with longer treatment retention. After 12 
years, the respective estimates for treatment retention 
were: DAM p.o. patients, 52.1% (95% CI at day 3,205: 
44.6–59.5%); DAM i.v. patients, 15.7% (95% CI at day 
4,373: 14.1–17.3%).
 Retention in a maintenance study is often time-depen-
dent, with the highest dropout rate occurring shortly af-
ter receiving a new study medication. As the majority of 
patients in our study had already been using the study 
medication before the start of the study, this may have 
resulted in self-selection bias. It may be possible that in 
the patients who had been using the study medication 
before, people at higher risk of dropout had already 
dropped out by the time the study began, and thus, the 
high retention rate was caused mainly by these long-term 
heroin tablet users. We tested this potential bias by com-
paring the two groups, i.e. those who had been on DAM 
p.o. before the study began and those who started with 
DAM p.o. on the first day of the study. Though the con-
fidence intervals overlapped over the full study period 
( fig. 4 ), a formal log-rank test yielded a p value of 0.0326, 
pointing at a somewhat faster dropout of patients set on 
tablets in October 2003.
 Major Study Endpoint: Adverse Events 
 The physician-verified rate of serious adverse events 
was 0.01 events per application year, or 1% of affected pa-
tients among the exclusively oral substitution group (ITT 
analysis) during the second year of observation ( table 1 , 
which also gives adverse events during first observation 
year). This rate was lower than during the first observa-
tion year. Combined medication strategies were associ-
ated with a rate of 0.005 events per application year (0.5% 
of affected patients), again lower than the first observa-
tion year. Neither group deviated significantly from the a 
priori fixed tolerance limit of 4.3% of affected patients.
 The two serious events (death of one patient in India 
on study leave substituted by methadone; admission to 
psychiatric hospital for stabilization and cocaine with-
drawal) were not causally related to the study medication. 
After January 2006 (end of second observation year), reg-
istration and monitoring of adverse events followed the 
routine procedures of Swiss HAMT and, thus, were not 
available for the purpose of this study.
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 Fig. 3.  Retention rate (ITT) in groups 1 and 2 combined (tablets 
only) versus group 3 (tablets and DAM i.v. or other oral opiods) 
since start of oral medication (Kaplan-Meier estimator). 
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Table 1.  Incidence of serious adverse events
Group 1
(only IR
tablets)
Group 2 
(IR + SR 
tablets)
Groups 1 and 2
combined
Group 3
(combination of tablets 
with opioid medication)
Total
Observation period 1: November 1, 2003 to January 5, 2005
Events 0 5 5 7 12
Patients with event 0 5 5 5 10
Patients under risk 40 88 128 237 365
Days under risk 15,999 32,434 48,433 90,608 139,041
Events per year 0.000 0.056 0.038 0.028 0.032
95% CI (Poisson) lower limit 0.000 0.019 0.012 0.011 0.016
95% CI (Poisson) upper limit 0.081 0.126 0.086 0.057 0.054
Rate of persons with serious events per year 0.000 0.056 0.038 0.020 0.026
95% CI (Poisson) lower limit 0.000 0.019 0.012 0.007 0.013
95% CI (Poisson) upper limit 0.081 0.126 0.086 0.046 0.048
Mean observation time per patient, years 1.10 1.00 1.03 1.05 1.04
Observation period 2: January 6, 2005 to January 5, 2006
Events 0 1 1 1 2
Patients with event 0 1 1 1 2
Patients under risk 37 68 105 203 308
Days under risk 12,860 24,121 36,981 68,137 105,118
Events per year 0.000 0.015 0.010 0.005 0.007
95% CI (Poisson) lower limit 0.000 0.000 0.000 0.000 0.000
95% CI (Poisson) upper limit 0.014 0.052 0.034 0.018 0.019
Rate of persons with serious events per year 0.000 0.015 0.010 0.005 0.006
95% CI (Poisson) lower limit 0.000 0.000 0.000 0.000 0.000
95% CI (Poisson) upper limit 0.014 0.051 0.033 0.017 0.017
Mean observation time per patient, years 0.95 0.97 0.96 0.92 0.94
0
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0.7
0.8
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1.0
1
Days since individual start of DAM p.o.
366 731 1,096 1,461 1,826 2,191 2,556 2,921
Before Oct. 2003 (lower CI)
Before Oct. 2003 (upper CI)
Oct. 2003 (upper CI)
Oct. 2003 (lower CI)
 Fig. 4. Retention rate of patients receiving 
DAM tablets prior to October 2003 (start 
of drug approval study) versus the rate 
since October 2003. 
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 Discussion 
 Chronic dependent opioid users are characterized by 
the persistence of opioid use regardless of the difficulties 
they experience with their health, the law and in their so-
cial environment. DAM tablets offer an effective mainte-
nance treatment for the specific subgroup of refractory 
and severely addicted opioid users who do not inject. 
Overall, DAM p.o. substitution has proven to be a safe 
and feasible treatment for severely opioid-dependent peo-
ple. Thus, our results may be generalizable to a selection 
of patients willing to try oral administration. Safety was 
comparable to DAM i.v., which is already accepted as a 
regular medication by the Swiss authorities for the treat-
ment of this group. Feasibility, as measured by treatment 
retention, was even significantly better in DAM p.o. sub-
stitution.
 There may be alternative settings for nonintravenous 
DAM substitution. For instance, oral morphine has been 
suggested as a second-line substitution medication  [12] , 
and inhalable DAM has been tested in the Netherlands 
with success  [11] . We hope that these and other alterna-
tives will be tested against DAM p.o. in randomized tri-
als. For inhalable DAM, different forms for inhalation 
from the Dutch may have to be found to be accepted as 
medication in some countries, but in principle this is pos-
sible. Our hypothesis would be that DAM p.o. would be 
more effective than other oral opioids including mor-
phine, as the bioavailability is higher and a faster onset 
can be reached  [18] . But these are hypotheses based on 
basic research; the effects have to be confirmed in ran-
domized trials under real-life conditions.
 There were some potential methodological limitations 
concerning the self-selection process of the participants 
in our study. A portion of our patients might have chosen 
oral application of DAM because their attitude towards 
risks associated with intravenous application had been 
changing and this change reflected a general process of 
dissociation from the illegal drug scene. This process 
could then have determined the low rate of dropouts as 
well as the low illegal consumption and the observed low 
rate of serious adverse events. This argument could only 
be countered by a randomized controlled clinical trial 
comparing intravenous versus oral application mode of 
DAM, which would be unethical.
 We found hints on a faster dropout process of the 74 
patients (18%) who started with tablets in October 2003. 
Whether this means the retention rates of the oral DAM 
groups are positively flawed by omitting potential former 
dropouts prior to our study cannot be concluded with 
certainty. It also seems plausible that the historical situa-
tion in autumn 2003 was understood by the treating phy-
sicians as a ‘last chance’ to change over the substitution 
medication of their patients to oral DAM for a long time 
period, and therefore they recruited in October 2003 a 
group of patients who were less suited for oral substitu-
tion than the previous subgroup.
 It may also be argued that the reported retention was 
only possible because the patients were recruited mainly 
from patients already in maintenance treatment, thus ex-
cluding the high rate of dropouts in the initial treatment 
period  [6, 10] . Three indirect arguments could be made: 
opioid addiction is a chronic relapsing disease and, thus, 
for many opioid-dependent patients, life has been a suc-
cession of episodes inside treatments and untreated epi-
sodes. Even people entering treatment after 1 year outside 
treatment have often had multiple treatment episodes be-
fore  [10, 22] , and vice versa: cohorts of originally untreat-
ed opioid users show a high prevalence of maintenance 
treatment episodes after some time  [23] . The success of 
maintenance treatment seems to be relatively indepen-
dent of prior history. A German trial did not find signif-
icant differences in effectiveness of heroin-assisted treat-
ment between people already in methadone treatment or 
outside the treatment system  [10] . Furthermore, in the 
Swiss study, the success of treatment, as defined by reten-
tion rate, was independent of whether it was a first, sec-
ond or third treatment episode  [24] . Therefore, we would 
hypothesize that the effectiveness of DAM p.o. is inde-
pendent of whether it is a first treatment episode or if the 
patient enters this treatment from another treatment. 
Such a hypothesis must be further examined in new stud-
ies.
 Finally, the quite ‘liberal’ definition of retention in the 
Swiss HAMT is also covering periods of methadone sub-
stitution during patients’ holidays, for instance. There-
fore comparing these retention rates with stricter defini-
tions from outside Switzerland might face a potential 
‘overestimation’ of retention for Swiss patients. But this 
argument does not apply for comparisons within the 
Swiss HAMT.
 Notwithstanding the methodological limitations 
mentioned above, the results of our study strongly sup-
port the continuation of this treatment for all patients 
with the mentioned indications for the oral application of 
HAMT. While other studies may clarify the optimal ap-
plication of DAM tablets in combination with other opi-
oids or in exclusive prescription, the current practice 
clearly seems justified by the clinical results.
 Frick  /Rehm  /Zullino  /Fernando  /
Wiesbeck  /Ammann  /Uchtenhagen  
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 Another open question concerns the application of 
oral DAM as a first-line treatment for refractory opioid 
users. Currently, intravenous application is the default for 
everybody, except for users of illegal opioids who do not 
inject. Given the results above, it should be considered 
whether the continuation of the status quo of providing 
a potentially more harmful treatment option (intrave-
nous prescription) as a first-line treatment is justified. Of 
course, we would need more research with better design 
and including different endpoints before a truly evidence-
based decision to make oral DAM a first-line treatment 
for refractory opioid users can be made.
 Finally, we hope that our results with respect to DAM 
tablets will lead to a further ‘normalization’ of the role of 
HAMT within the continuum of care. Meanwhile dia-
morphine tables received orphan drug status in Switzer-
land. In a time when substitution treatment finally has 
been accepted as the standard of evidence-based opioid 
treatment  [1, 2] , we see no reason why heroin tablets 
should be considered any different from other forms of 
opioid substitution. As already indicated above, further 
randomized trials using different types of opiates should 
be conducted to provide the necessary evidence of future 
guidelines.
 
